Despite volume lag, drug firms hike price as domestic sales rebound

Motilal Oswal analysts also said that while price growth for non-NLEM products stood at 4.8 per cent YoY, NLEM products saw a price rise of 3.6 per cent

Domestic pharma sales bounced back in September, but what’s interesting is that this rise was led by pricing growth.
 

During the pandemic — when people are avoiding hospitals and clinics and fresh prescription growth has slowed down — the volume growth in the domestic market has also fallen. However, a deeper look at the data shows that the volume decline too has been slowing — it fell 4 per cent year-on-year in September against 9.2 per cent decline in August.
 

Motilal Oswal analysts said for the September quarter, while the volumes fell 6.5 per cent YoY, price growth came in